Clinical Trial Update: Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies [Phase 1]

View source ↗

Summary

Elenestinib (BLU-263) in a Phase 1 study for Advanced Systemic Mastocytosis and KIT-altered hematologic malignancies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Mastocytosis

Drugs mentioned

• Elenestinib (elenestinib)

Snippet

Sponsor: Blueprint Medicines Corporation | Conditions: Advanced Systemic Mastocytosis | Phase 1 | Status: TERMINATED